Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | AGXT | P21549 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1868023 | 0.83 | MAOA (0.59) | MAOACA1CA2CA4CA7 | |
| SCHEMBL7422121 | 0.81 | MAOA (0.40) | MAOAMTNR1AMTNR1BMAOBALDH1A1 | |
| SCHEMBL31181340 | 0.79 | MTNR1A (0.57) | CA1CA2CA7CA9MTNR1A | |
| SCHEMBL11560772 | 0.79 | MTNR1A (0.40) | MAOACA2CA9MTNR1AMTNR1B | |
| SCHEMBL7214204 | 0.79 | MAOA (0.39) | MAOAMTNR1AMTNR1BMAOBALDH1A1 | |
| SCHEMBL4392690 | 0.79 | GRM5 (0.40) | MAOAMTNR1AMTNR1BMAPTL3MBTL1 | |
| SCHEMBL16295456 | 0.79 | MTNR1A (0.57) | CA1CA2CA7CA9MTNR1A | |
| SCHEMBL573866 | 0.78 | MAOA (0.58) | MAOACA1CA2CA4CA7 | |
| SCHEMBL3224927 | 0.77 | MAOA (0.55) | MAOAMTNR1AMTNR1BMAOBALDH1A1 | |
| SCHEMBL1710499 | 0.77 | MAOA (0.65) | MAOACA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294212-B2 | Inhibitors of the kynurenine pathway | CURADEV PHARMA, PVT. LTD. (IN) | 2019-05-21 | — | — | US | disclosed |
| CN-105209449-B | Inhibitors of the kynurenine pathway | 库拉德夫制药私人有限公司 | 2019-02-01 | — | — | CN | disclosed |
| EP-2970173-B1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD (IN) | 2018-05-09 | — | — | EP | disclosed |
| US-20180030026-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PVT LTD | 2018-02-01 | — | — | US | disclosed |
| US-9815811-B2 | Inhibitors of the kynurenine pathway | CURADEV PHARMA, PVT. LTD. (IN) | 2017-11-14 | — | — | US | disclosed |
| US-9676901-B2 | Conjugated polymers | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676901-B2 | Conjugated polymers | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676901-B2 | Conjugated polymers | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20160046596-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD. (IN) | 2016-02-18 | — | — | US | disclosed |
| EP-2970173-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | Curadev Pharma Private Ltd. (IN) | 2016-01-20 | — | — | EP | disclosed |
| WO-2013159862-A1 | CONJUGATED POLYMERS | MERCK PATENT GMBH (DE) | 2013-10-31 | — | — | WO | disclosed |
| WO-2009049028-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USE AS JANUS KINASE MODULATORS | TARGEGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049028-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USE AS JANUS KINASE MODULATORS | TARGEGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009026345-A1 | THIAZOLIDINONE COMPOUNDS, AND METHODS OF MAKING AND USING SAME | TARGEGEN INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026345-A1 | THIAZOLIDINONE COMPOUNDS, AND METHODS OF MAKING AND USING SAME | TARGEGEN INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| US-7166586-B2 | Sulfonamide lactam inhibitors of FXa and method | BRISTOL MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | O'CONNOR STEPHEN P (US) | 2004-09-23 | — | — | US | disclosed |
| EP-1358178-A2 | SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA | Bristol-Myers Squibb Company (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6555542-B1 | Factor Xa (FXa); useful as anticoagulants in the treatment of cardiovascular diseases associated with thrombosis | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-29 | — | — | US | disclosed |
| WO-2002060894-A2 | SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294212-B2 | Inhibitors of the kynurenine pathway | IDO1, IDO2, KYNU | MAOA 11/4885CA1 1445/4885CA2 1670/4885 |
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | STS, SULT1E1, F8 | MAOA 978/4885CA1 2723/4885CA2 3142/4885 |
| US-20180030026-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | IDO1, IDO2, KYNU | MAOA 11/4885CA1 1445/4885CA2 1670/4885 |
| US-20160046596-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | IDO1, KYNU, IDO2 | MAOA 11/4885CA1 1280/4885CA2 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.